Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Metabolic Syndrome X
Interventions: Nutritional and Dietary Manipulation; Other
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections
Interventions: VH4004280, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Systemic Lupus Erythematosus
Interventions: DS-7011a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 12
States / cities: Anniston, Alabama • North Little Rock, Arkansas • North Miami Beach, Florida + 9 more

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Sorafenib+YIV-906, Sorafenib+placebo; Drug
Lead sponsor: Yiviva Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Flushing, New York • Lake Success, New York • New York, New York + 1 more

Conditions: Posttraumatic Stress Disorder
Interventions: Therapy, Midomafetamine, Placebo; Behavioral · Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Boulder, Colorado + 7 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Wobe-Mugos E, melphalan, prednisone, quality-of-life assessment; Drug · Procedure
Lead sponsor: Medsearch; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 15 more

Conditions: Psoriasis Vulgaris
Interventions: PTH (1-34) Gel / Placebo Gel; Drug
Lead sponsor: Manhattan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: San Diego, California • Ormond Beach, Florida • Fridley, Minnesota + 1 more

Conditions: Bacterial Vaginosis
Interventions: GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Cystocele, Uterine Prolapse, Urinary Incontinence
Interventions: grafted anterior prolapse repair, sutured anterior vaginal prolapse repair; Device · Procedure
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Downey, California

Conditions: Age-Related Maculopathy
Interventions: RN6G, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 83
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Conditions: Plaque Psoriasis
Interventions: Tazarotene Cream, 0.05%, Vehicle, Reference: Tazorac Cream, 0.05%; Drug
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 866 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: Autism Spectrum Disorder
Interventions: Early Start Denver Model (ESDM), Early Intensive Behavioral Intervention (EIBI); Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 15 Months to 30 Months
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 3
States / cities: Sacramento, California • Nashville, Tennessee • Seattle, Washington

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline); Biological · Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 37
States / cities: Hoover, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more

Conditions: DIEP Flap, Breast Reconstruction, Breast Cancer
Interventions: Use of ORASIS Device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Healthy Volunteers
Interventions: OROS methylphenidate HCl, SODAS methylphenidate HCl; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Gastrointestinal Health, Immune Health, Cardiovascular Health, Digestive Health
Interventions: Bacillus subtilis BS50 spore preparation, Maltodextrin; Dietary Supplement
Lead sponsor: BIO-CAT Microbials, LLC; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Malaria
Interventions: D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: Fatigue
Interventions: Fisetin followed by Placebo, Placebo followed by Fisetin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Influenza
Interventions: Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Pain, Postoperative
Interventions: Bupivacaine Hydrochloride, Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ischemic Stroke
Interventions: NeuroThera® Laser System; Device
Lead sponsor: PhotoThera, Inc; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 51
States / cities: Fort Smith, Arkansas • Berkeley, California • Encinitas, California + 45 more

Conditions: Alcohol Dependence, Alcohol Abuse
Interventions: Naltrexone, Modified Behavioral Self-Control Psychotherapy, Brief Behavioral Compliance Enhancement Therapy, Placebo; Drug · Behavioral
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo; Drug
Lead sponsor: Zydus Lifesciences Limited; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more

Conditions: Migraine Headache
Interventions: DFN-15 Active, DFN-15 Placebo; Drug · Other
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Search by objective public record fields.

Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

Intervention Effects of Intensity and Delivery Style for Toddlers With Autism

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

ORASIS in Breast Reconstruction

A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults

Effect of Bacillus Subtilis BS50 Supplementation on Gastrointestinal Symptoms in Healthy Adults

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Bupivacaine Hydrochloride for Pain Control in Cutaneous Surgery

Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)

Medication and Counseling for Controlled Drinking

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

Efficacy, Tolerability, and Safety Study of DFN-15